4/22
07:50 am
cgtx
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer's Disease [Yahoo! Finance]
Medium
Report
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer's Disease [Yahoo! Finance]
4/22
07:30 am
cgtx
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
Low
Report
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
4/18
08:00 pm
cgtx
Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's [Seeking Alpha]
Medium
Report
Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's [Seeking Alpha]
4/2
07:30 am
cgtx
Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference
Medium
Report
Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference
4/1
07:41 am
cgtx
Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer's Disease on April 12, 2024 [Yahoo! Finance]
Low
Report
Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer's Disease on April 12, 2024 [Yahoo! Finance]
4/1
07:30 am
cgtx
Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024
Low
Report
Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024
3/27
09:40 am
cgtx
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Neutral
Report
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/27
08:07 am
cgtx
Cognition Therapeutics, Inc. (NASDAQ: CGTX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $9.00 price target on the stock.
Low
Report
Cognition Therapeutics, Inc. (NASDAQ: CGTX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $9.00 price target on the stock.
3/26
07:17 am
cgtx
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update [Yahoo! Finance]
3/26
07:00 am
cgtx
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
Low
Report
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
3/15
07:30 am
cgtx
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results
Low
Report
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results
3/14
04:05 pm
cgtx
Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock
Medium
Report
Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock
3/12
02:11 am
cgtx
Cognition Therapeutics announces pricing of stock offering to raise $11.5M [Seeking Alpha]
Medium
Report
Cognition Therapeutics announces pricing of stock offering to raise $11.5M [Seeking Alpha]
3/11
08:26 pm
cgtx
Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock [Yahoo! Finance]
Medium
Report
Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock [Yahoo! Finance]
3/11
08:16 pm
cgtx
Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock
Medium
Report
Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock
3/11
04:27 pm
cgtx
Cognition Therapeutics Announces Proposed Public Offering of Common Stock [Yahoo! Finance]
Medium
Report
Cognition Therapeutics Announces Proposed Public Offering of Common Stock [Yahoo! Finance]
3/11
04:05 pm
cgtx
Cognition Therapeutics Announces Proposed Public Offering of Common Stock
Low
Report
Cognition Therapeutics Announces Proposed Public Offering of Common Stock
3/6
07:38 am
cgtx
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer's Disease Studies [Yahoo! Finance]
Low
Report
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer's Disease Studies [Yahoo! Finance]
3/6
07:30 am
cgtx
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies
Low
Report
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies
2/26
07:45 am
cgtx
Cognition Therapeutics to Present at the TD Cowen Health Care Conference [Yahoo! Finance]
Medium
Report
Cognition Therapeutics to Present at the TD Cowen Health Care Conference [Yahoo! Finance]
2/26
07:30 am
cgtx
Cognition Therapeutics to Present at the TD Cowen Health Care Conference
Medium
Report
Cognition Therapeutics to Present at the TD Cowen Health Care Conference
2/6
08:59 am
cgtx
New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812 [Yahoo! Finance]
Low
Report
New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812 [Yahoo! Finance]
2/6
08:47 am
cgtx
New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812
Medium
Report
New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812